Recent Updates
Recently added Catalysts
INO Positive Sentiment Score: 60/100

INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

Wednesday, February 15, 2023 1 min read
Key Takeaway: INOVIO (NASDAQ:INO) is set to release its fourth quarter and year-end 2022 financial results after the market closes on March 1, 2023. The company will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. INOVIO is focused on developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases, leveraging its proprietary CELLECTRA® device to enhance immune responses.

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO will report its fourth quarter and year-end 2022 financial results, indicating ongoing business activity.
  • The company is focused on developing innovative DNA medicines for significant health issues.
  • A live conference call will allow for engagement with analysts, promoting transparency.

Full Press Release Details

PLYMOUTH MEETING, Pa., Feb. 15, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter 2022 financial results will be released after the market close on March 1, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.
Media: Jennie Willson (267) 429-8567 [email protected]
Investors: Thomas Hong (267) 440-4298 [email protected]
SOURCE INOVIO Pharmaceuticals, Inc.

21 %

more press release views with

Frequently Asked Questions

When will INOVIO release their fourth quarter 2022 results?

INOVIO will announce their fourth quarter 2022 results on March 1, 2023.

How can I attend INOVIO's financial results call?

You can attend INOVIO's financial results call via a live webcast at 4:30 p.m. ET.

What focus areas does INOVIO's research cover?

INOVIO focuses on DNA medicines for HPV-associated diseases, cancer, and infections.

What device does INOVIO use for delivering its DNA medicines?

INOVIO uses its investigational device, CELLECTRA®, to deliver DNA medicines.

Is there a Q&A session during the live conference call?

Yes, there will be a live Q&A session with analysts during the call.

Tags: INO Viatris Investor Conferences Healthcare INOVIO financial results Q4 2022 biotechnology HPV-associated diseases
Last updated: Feb 15, 2023